1. Rudi Jansen<br />Ferme Leceuix64400 EsquiuleFranceEmail: rudi.jansen@wanadoo.frTel: +33 559 39 60 88Mobile: +33 671 21 25 16Evagoras PalikaridesApartment 3aAglantzia2108 NicosiaCyprus<br />30 Second - BUSINESS PROFILEA strong track record of sales and profit growth running major international companies in the pharmaceutical sector, including successful turnarounds. Extensive local experience in US, European and Indian business cultures. Result-oriented, hands-on management style, working both autonomous as well as on senior management team and Board level. Experienced fund-raiser and well acquainted with academic and industry collaboration models.30 Second - PERSONAL PROFILEEnjoys a busy and result driven working environment as well as his family life at home in the country. His leisure time is devoted to cooking, art, theatres, literature and getting together with good old friends, as well as observing the wildlife and enjoying the quiet and peaceful surroundings of his countryside home.The BEST MANAGEMENT he has hadGood communicators, who gave Rudi the responsibility and opportunity to implement the company strategy and objectives. The WORST MANAGEMENT he has had Poor communicators, who worked with poorly researched “off the cuff” strategies subject to constant change, were distrustful and inconsistent.Rudi in KEY WORDS:Business Development A proven ability to generate quick income stream combined with the capability to build lasting and profitable client relationships. Proven fund raising capabilities from a pan-European perspective.Enthusiasm & Energy Looks continuously for new growth opportunities and new developments and has an energetic business approach.Entrepreneurial Leadership A strong, entrepreneurial leader who leads by example, values his team for its individual qualities and encourages each team member to perform at his best, but does not refrain from making difficult but necessary business decisions.Experience Has over 25 years of international pharma experience, covering OTC, generics and patented pharmaceuticals.Strong track record with drug development programs between industry and academia. Independence Achieves best results when given the space to operate in order to succeed and implement the necessary strategy to success.Integrity Has a firm commitment to the company and its philosophy and strives to establish trust and credibility with both his team, his superiors and external contacts.Knowledge Has built up substantial knowledge of the pharmaceutical industry in Eastern & Western Europe as well as India and has gained in depth knowledge of the business cultures of the individual countries involved.Team spirit Enjoys working with true and equally enthusiastic professionals at every level.<br /> <br />Objective<br />To leverage significant executive level and experience from the pharmaceutical industry. Potentially branching out into the CRO and OTC industry. Interested in Executive positions and/or Board directorships.<br /> <br />Experience<br />September 2008 – February 2010<br />Strides Arcolab (Publicly traded company 2,000-3,000 employees)<br />Industry: European division of a Generic Pharmaceutical R&D and manufacturing company<br />CEO Europe Strides Arcolab<br />The European division comprises two manufacturing sites and four Sales/Marketing companies. <br />Initiated, developed and implemented a business plan to convert a fragmented business structure into a pan-European company. Developed a regional structure for business development and regulatory affairs. Oversaw major upgrade of sterile manufacturing unit and started to bring in first class European management team. Opened an EER office and initiated J.V. partnership in Eastern Europe. Initiated and completed contract manufacturing/licensing contracts. Completed a European regulatory filing strategy for the first 35 hospital injectable products. Completed acquisition of mature product brands for UK business. Started succession planning for M.D.’s in Poland, Norway and Italy. Appointed M.D. for UK business<br />September 2004 – July 2008 <br />Intsel Chimos (Privately traded company, 15-20 employees) <br />Industry: Paris based speciality pharmaceutical company, providing hospitals with speciality medicine under a temporary marketing authorization.<br />Managing Director and Member of the Board <br />Assignment focused on growing the hospital injectable business and to sort out the management issues that hampered the development of the company. Management team was replaced by dynamic and entrepreneurial individuals with a strong international background. Portfolio has been realigned. The pharmaceutical business on the ATU side doubled from 2005 – 2007 with a net margin of +50%. Inlicensed portfolio of hospital based intensive care pharmaceuticals. Successfully outlicensed Prostaglandin portfolio to third parties.<br />Developed a comprehensive business plan and completed a supported 6 million Euro take over bid for the business in collaboration with AGF (Allianz) in spring 2008.<br />April 1996 – September 2004 <br />Jansen Pharma Consultants Ltd <br />Industry: Scotland based consultancy service for the pharmaceutical sector in close collaboration with Deloitte & Touche (London, UK)<br />Founder & President <br />The business focused on merger and acquisition assignments. Excellent working relations were established and are maintained with some of the leading venture capital organizations (3i, Barclays, Industry Capital, Allianz, Advent, Aelios, Barclays, G-E Capital). <br />MERGER AND ACQUISITION PROGRAM (M&A)<br />One out of three candidates selected in the United Kingdom by Deloitte & Touche to participate in M&A program (Management Buy In/Buy Out): March 1999- September 2004.<br /> <br />Key Achievements<br />Searched and identified between 20-25 pharmaceutical acquisition targets.<br />Led acquisition/due diligence team on six separate occasions.<br />Evaluated businesses and developed supported bids ranging from $ 45-160 million.<br />Developed six comprehensive strategy and business plans for acquisition targets.<br />Developed good working relationships with some of the world’s leading venture capital organisations. <br />Successfully brokered acquisition of Chefaro (Akzo Nobel) by Omega Pharma in a $145 million transaction assisted by Deloitte&Touche, corporate finance department, London, United Kingdom (January 2001).<br />Completed acquisition of Brahms Artzneimittel/Herbert Artzneimittel (Wiesbaden, Germany) in a USD 5 million transaction by MEDA Pharma (Stockhom Sweden) (December 2002/January2003). <br />August 1997 – March 1999 <br />The Wallis Laboratories (Privately held UK company, 200-300 employees) Industry: UK based company specialized in the development, manufacturing and marketing of OTC product portfolios<br />Managing Director and Member of the Board<br />A business turnaround assignment, with the objective to build a profitable business within two years. Changed the business model from high volume/low margin to high margin/low volume products. Built a new team of unit directors and improved financial management through the introduction of a new computer system. Achieved a growth of gross contribution percentage from 44 to 60 in 18 months time and reversed a significant loss situation to a healthy PBT.<br />October 1976 – April 1996 <br />Pharmacia / UpJohn (Publicly traded company, 25,000 – 30,000 employees)<br />Industry: US based company specializing in the development, manufacturing and marketing of hospital and retail prescription medicine.<br />January 1995 – April 1996 (Pharmacia / UpJohn)<br />Regional Business Director EER <br />Based in Prague, Czech Republic, this position was accountable for sales and earnings in the region and to develop and coordinate country specific business plans. Completed the restructuring of the marketing processes and supervised the introduction of three new product entities. Revised plans for 1995 and reversed a downward trend culmulating in an increase of the budget for the year of 11%<br />July 1992 – January 1995 (Pharmacia / UpJohn)<br />Director Medical Sciences Liaison Europe, Far East and Latin America<br />Based in Michigan, US, this position was responsible for the coordination, direction and the implementation of regional (pre)marketing strategies in core business disciplines. Developed and implemented regional pre-marketing projects in Europe and Pacific Rim/Far East. Established excellent rapport with worldwide marketing staff; regional and subsidiary line management.<br />September 1989 – July 1992 (Pharmacia / UpJohn)<br />Regional Medical Sciences Liaison Manager Europe and MENA <br />Based in Brussels, Belgium, this position was responsible for development and implementation of planned introductions for hospital products and initated and developed a formation of pan-European management task forces to implement regional projects. <br />July 1985 – September 1989 (Pharmacia / UpJohn)<br />Sales Marketing Director<br />Based in Ede, the Netherlands, this position was responsible for achieving annual sales budget and developing the subsidiary marketing plan.<br />Board Memberships<br />Strides Poland, Warsaw , Poland (2008 – 2010)<br />Beltapharm, Milan, Italy (2008 – 2010)<br />Co-pharma, Watford, U.K (2008- 2010)<br />Intsel Chimos, Paris, France (2004 – 2008)<br />Director of Jansen Pharma Consultants Limited, London, United Kingdom (1999 – 2004)<br />Board of Directors of Phytogen Lifesciences, Vancouver B.C, Canada (1999 - 2001) <br />Business Advisorships<br />Brahms Diagnostics GmbH, Hennigsdorf, Germany (2003-2004)<br />Deloitte & Touche, Corporate Finance, London, UK (2000-2004)<br />Torrent Pharma Industries, India (2002-2003)<br />Herbert Artzneimittel GmbH, Germany (2002-2003)<br />Brahms Artzneimittel GmbH, Frankfurt, Germany (2001-2002)<br />Troponwerke (ex-Bayer), Koln, Germany (1998-2000)<br />Phytogen Lifesciences Inc./Phytogen Pharmaceuticals Inc., Vancouver, Canada: (1998-2000)<br />Education<br />HAVOAlexander Hegius College, Deventer, the Netherlands<br />Graduate MarketingInstitute for Social Sciences, the Hague, the Netherlands<br />Post-Graduate Infectious Diseases, Leiden University, Medical School, Boerhave<br />Languages<br />English, Dutch, German and French (fluent in all languages)<br />Presentations<br />”Alternative Investment Strategy on Raising Cash to Ensure Biotech Future” <br />The CEO Biotech Club for Bio-pharmaceutical & bio-technology industry leaders, <br />Paris, October 2008 – rated best presentation given<br />“ Interim Management and the Pharmaceutical Industry” <br />Institute for Interim Management and RSA Interims, Hatfield (London), UK, February 2004 – rated best presentation given<br />“The Global Challenge Facing Corporations in the Coming Decade” <br />National Institutes of Health, Washington D.C. United States of America, May 1996 <br />“Critical Issues Facing the Modern Global Corporation” <br />American Graduate School of International Management, Paris, France, June 24, 1992<br /> <br />References<br />Available upon request.<br />